Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- CMS Rebate Shift & NICE ThresholdEpisode 123 — 28 September 2026CMS proposes Medicaid rebate reforms, ICER expands early-phase advice, FDA updates RWE guidance for accelerated approvals, and NICE consults on ultra-orphan cost-effectiveness thresholds.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast12 min
- Access Erosion & Value SignalsEpisode 122 — 27 September 2026Examining hospital profit warnings, subcutaneous Leqembi's impact, FTC insulin settlements, and ICER's early-phase scientific advice expansion.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- FDA RWE Guidance & CMS Star RatingsEpisode 121 — 26 September 2026Examining FDA's RWE guidance, CMS Star Ratings changes, ICER's gene therapy framework, and NICE's RWE updates.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HTA Methodological Shifts & Pricing PressuresEpisode 120 — 25 September 2026Examining operational hurdles in CMS Part D redesign, EMA's adaptive licensing expansion, NICE's threshold consultation, and FDA's RWE guidance implications.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HCA Warning, Leqembi SubQ, FTC CVS, ICER AdviceEpisode 119 — 24 September 2026HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value; FTC-CVS settlement exposes PBM practices; ICER expands early-phase scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Profit Warnings & Scientific AdviceEpisode 118 — 23 September 2026HCA's profit warning signals systemic access challenges, while subcutaneous Leqembi and FTC-CVS settlement reshape insulin access dynamics. ICER expands early-phase scientific advice to de-risk development.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HCA Warning, Leqembi Shift, Insulin PBM, ICER AdviceEpisode 117 — 20 September 2026Hospital system profit warnings signal access erosion; subcutaneous Alzheimer's delivery reshapes value narratives; FTC targets PBM insulin pricing; ICER expands early-phase evidence strategy.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- Supportive Care RWE, Cell Therapy Budget Impact, Patient-Centric HTAEpisode 116 — 19 September 2026Examining RWE gaps in supportive care for rare diseases, budget impact challenges for cell/gene therapies, and patient-centric shifts in European HTA methodologies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HCA Warning, Leqembi, FTC, ICER ExpansionEpisode 115 — 18 September 2026HCA's profit warning signals US access challenges; subQ Leqembi, FTC insulin settlement, and ICER advice expansion highlight evolving market access dynamics.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- Star Ratings, Decentralized Trials, Gene Therapy Frameworks, RWE GuidanceEpisode 114 — 17 September 2026This week: CMS Medicare Advantage Star Ratings methodology shifts, FDA decentralized trials guidance, ICER's new gene therapy framework, and NICE's updated RWE guidance.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.